New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 15, 2014
09:23 EDTEW, ZMH, NUVA, COV, SYK, STJ, BSX, IARTBarclays medical supplies/devices analysts hold analyst/industry conference call
Medical Supplies & Devices Analysts provide a review of the recently held Barclay's Medtech Symposium on an Analyst/Industry conference call. Relevant companies COV, BSX, STJ, MDT, EW, NUVA, IART, SYK and ZMH may be discussed on the Analyst/Industry conference call to be held on April 15 at 10:30 am.
News For BSX;COV;EW;STJ;NUVA;IART;SYK;ZMH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 23, 2015
10:24 EDTIARTIntegra LifeSciences management to meet with Jefferies
Meeting to be held in New York on November 30 hosted by Jefferies.
November 19, 2015
16:43 EDTBSXBoston Scientific receives CE Mark for next generation WATCHMAN FLX
Boston Scientific announced that the first implants of the WATCHMAN FLX Left Atrial Appendage Closure, or LAAC, Device - the latest generation of the WATCHMAN Device - occurred in Europe following CE mark approval.
16:34 EDTEWEdwards Lifesciences approves two-for-one stock split
Edwards Lifesciences approved a two-for-one split of the company's outstanding shares of common stock to be effected as a 100% stock dividend. This will be the company's second stock split since it went public in April 2000. Stockholders of record at the close of business on November 30 will be issued one additional share of common stock for each share owned as of that date. The additional shares will be distributed on December 11. The stock split will increase the number of common shares outstanding from approximately 108M shares as of the record date, to approximately 216M shares.
10:42 EDTBSXLeerink medical devices analyst holds an analyst/industry conference call
Subscribe for More Information
08:02 EDTSTJSt. Jude Medical announces FDA approval of Proclaim Elite SCS system
Subscribe for More Information
November 17, 2015
10:02 EDTSYKHigh option volume stocks
Subscribe for More Information
November 13, 2015
10:00 EDTSYKOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Abbott (ABT) downgraded to Neutral from Buy at Goldman... Advance Auto Parts (AAP) downgraded after Q3 miss at Sterne Agee CRT... CafePress (PRSS) downgraded to Underperform from Market Perform at Raymond James... (CTRP) downgraded to Outperform from Strong Buy at Raymond James... CubeSmart (CUBE) downgraded to Outperform from Strong Buy at Raymond James... Deutsche Bank (DB) downgraded to Neutral from Buy at Citi... Digital Ally (DGLY) downgraded to Neutral from Buy at Roth Capital... El Pollo Loco (LOCO) downgraded to Neutral at Baird... F5 Networks (FFIV) downgraded to Market Perform from Outperform at William Blair... FirstMerit (FMER) downgraded on stock outperformance at Raymond James... Fly Leasing (FLY) downgraded to Underweight from Neutral at JPMorgan... GameStop (GME) downgraded on valuation, digital impact at Pacific Crest... Histogenics (HSGX) downgraded to Neutral from Buy at BTIG... MaxPoint (MXPT) downgraded to Hold from Buy at Needham... Memorial Resource (MRD) downgraded to Outperform at Scotia Howard Weil... Rite Aid (RAD) downgraded to Neutral from Overweight at JPMorgan... Rubicon Minerals (RBY) downgraded to Sell from Hold at Canaccord... SABMiller (SBMRY) downgraded to Hold from Buy at Berenberg... Sensata (ST) downgraded at SunTrust... Stryker (SYK) downgraded to Neutral from Buy at Goldman.
08:01 EDTBSXConsultant says coverage decision positive for Boston Scientific, says Stifel
Subscribe for More Information
06:27 EDTSYKStryker downgraded to Neutral from Buy at Goldman
Subscribe for More Information
06:24 EDTSYKMedtronic upgraded to Conviction Buy from Buy at Goldman
Goldman Sachs analyst David Roman upgraded Medtronic (MDT) to Conviction Buy saying the stock's risk/reward is compelling at current levels. The company's fundamentals are the strongest in nearly a decade amid improving end-markets, new product launches and financial flexibility, Roman tells investors in a research note. He raised his price target for shares to $90 from $87. Roman removed Stryker (SYK) from the Conviction List and also downgraded Abbott (ABT) to Neutral.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use